1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC).
Saved in:
| Title: | 1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC). |
|---|---|
| Authors: | Chehrazi-Raffle, A.1 (AUTHOR), Muddasani, R.1 (AUTHOR), Dizman, N.1 (AUTHOR), Hsu, J.1 (AUTHOR), Meza, L.1 (AUTHOR), Zengin, Z.B.1 (AUTHOR), Malhotra, J.1 (AUTHOR), Chawla, N.1 (AUTHOR), Lyou, Y.M.1 (AUTHOR), Dorff, T.1 (AUTHOR), Contente-Cuomo, T.2 (AUTHOR), Dinwiddie, D.2 (AUTHOR), McDonald, B.3 (AUTHOR), Trent, J.2 (AUTHOR), Murtaza, M.3 (AUTHOR), Pal, S.K.1 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1223-S1223. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.1582 |
